Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 85.69 USD -0.36% Market Closed
Market Cap: 9.1B USD
Have any thoughts about
Intra-Cellular Therapies Inc?
Write Note

Intra-Cellular Therapies Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intra-Cellular Therapies Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Revenue
$613.7m
CAGR 3-Years
106%
CAGR 5-Years
N/A
CAGR 10-Years
85%
Johnson & Johnson
NYSE:JNJ
Revenue
$87.7B
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$47.4B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$60.1B
CAGR 3-Years
-4%
CAGR 5-Years
14%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Revenue
$63.2B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Revenue
$40.9B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
7%
No Stocks Found

Intra-Cellular Therapies Inc
Revenue Breakdown

Breakdown by Geography
Intra-Cellular Therapies Inc

Not Available

Breakdown by Segments
Intra-Cellular Therapies Inc

Total Revenue: 464.4m USD
100%
Product Sales, Net: 462.2m USD
99.5%
Grant Revenue: 2.2m USD
0.5%

Intra-Cellular Therapies Inc
Glance View

Market Cap
9.1B USD
Industry
Pharmaceuticals

Intra-Cellular Therapies Inc. is a biopharmaceutical company at the forefront of developing innovative therapies for neuropsychiatric and neurological disorders. Founded in 2002 and based in New York City, the company focuses on addressing significant unmet medical needs in mental health, a field that has historically seen limited advancements. Its flagship product, Caplyta (lumateperone), is an atypical antipsychotic that has gained traction for its efficacy in treating schizophrenia and, more recently, bipolar depression. The approval of Caplyta by the U.S. FDA in December 2019 marked a significant milestone, positioning Intra-Cellular Therapies as a key player in the mental health space and enabling it to generate substantial revenue streams while establishing strategic partnerships for further drug development. As Intra-Cellular Therapies continues to expand its portfolio, the company is actively conducting clinical trials for additional indications beyond schizophrenia and bipolar disorder, targeting conditions like major depressive disorder and autism spectrum disorder. With a robust pipeline and an innovative approach to exploring intracellular signaling pathways, the company's research is poised to unlock new treatment modalities within the neuropsychiatric domain. For investors, Intra-Cellular Therapies presents a compelling opportunity, backed by a dedicated team and growing market demand for effective mental health treatments. Their commitment to changing the landscape of neuropsychiatric care, coupled with an emphasis on scientific research and patient outcomes, makes them a company to watch as they seek to transform lives and expand their influence in the biopharmaceutical arena.

ITCI Intrinsic Value
53.21 USD
Overvaluation 38%
Intrinsic Value
Price

See Also

What is Intra-Cellular Therapies Inc's Revenue?
Revenue
613.7m USD

Based on the financial report for Sep 30, 2024, Intra-Cellular Therapies Inc's Revenue amounts to 613.7m USD.

What is Intra-Cellular Therapies Inc's Revenue growth rate?
Revenue CAGR 10Y
85%

Over the last year, the Revenue growth was 46%. The average annual Revenue growth rates for Intra-Cellular Therapies Inc have been 106% over the past three years , and 85% over the past ten years .

Back to Top